Comparative Pharmacology
Head-to-head clinical analysis: PBZ versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PBZ versus XYZAL.
PBZ vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PBZ (phenylbutazone) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It also has uricosuric effects.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
25-50 mg orally every 4-6 hours as needed; not to exceed 300 mg/day. For severe allergies: 25 mg intramuscularly or intravenously every 4-6 hours.
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in adults; prolonged in renal impairment (up to 24 hours).
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Renal excretion of unchanged drug (approximately 70-80%) with the remainder as metabolites. Biliary/fecal excretion accounts for <5%.
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category C
Category C
Antihistamine
Antihistamine